These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30928962)

  • 21. Prevalence and Risk Factors Associated with Adverse Drug Reactions among Previously Treated Tuberculosis Patients in China.
    Han XQ; Pang Y; Ma Y; Liu YH; Guo R; Shu W; Huang XR; Ge QP; DU J; Gao WW
    Biomed Environ Sci; 2017 Feb; 30(2):139-142. PubMed ID: 28292352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-tuberculosis drugs adverse reactions: a review of the Iranian literature.
    Kargar M; Mansouri A; Hadjibabaie M; Javadi M; Radfar M; Gholami K
    Expert Opin Drug Saf; 2014 Jul; 13(7):875-91. PubMed ID: 24935479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
    Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
    Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco.
    El Hamdouni M; Ahid S; Bourkadi JE; Benamor J; Hassar M; Cherrah Y
    Infection; 2020 Feb; 48(1):43-50. PubMed ID: 31165445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depression among patients with tuberculosis: determinants, course and impact on pathways to care and treatment outcomes in a primary care setting in southern Ethiopia--a study protocol.
    Ambaw F; Mayston R; Hanlon C; Alem A
    BMJ Open; 2015 Jul; 5(7):e007653. PubMed ID: 26155818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency and Management of Adverse Drug Reactions Among Drug-Resistant Tuberculosis Patients: Analysis From a Prospective Study.
    Massud A; Syed Sulaiman SA; Ahmad N; Shafqat M; Chiau Ming L; Khan AH
    Front Pharmacol; 2022; 13():883483. PubMed ID: 35747749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases.
    Jones J; Mudaly V; Voget J; Naledi T; Maartens G; Cohen K
    BMC Infect Dis; 2019 Jun; 19(1):544. PubMed ID: 31221100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical management of suspected hypersensitivity reactions to anti-tuberculosis drugs.
    Bermingham WH; Bhogal R; Arudi Nagarajan S; Mutlu L; El-Shabrawy RM; Madhan R; Krishnaswamy UM; Murali MR; Kudagammana ST; Shrestha R; Sumantri S; Christopher DJ; Mahesh PA; Dedicoat M; Krishna MT
    Clin Exp Allergy; 2022 Mar; 52(3):375-386. PubMed ID: 34939251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of scheduled monitoring of liver function during anti-Tuberculosis treatment in a retrospective cohort in China.
    Wu S; Xia Y; Lv X; Zhang Y; Tang S; Yang Z; Tu D; Deng P; Cheng S; Wang X; Yuan Y; Liu F; Hu D; Zhan S
    BMC Public Health; 2012 Jun; 12():454. PubMed ID: 22712786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse Drug Reactions Reported to a National HIV & Tuberculosis Health Care Worker Hotline in South Africa: Description and Prospective Follow-Up of Reports.
    Njuguna C; Stewart A; Mouton JP; Blockman M; Maartens G; Swart A; Chisholm B; Jones J; Dheda M; Igumbor EU; Cohen K
    Drug Saf; 2016 Feb; 39(2):159-69. PubMed ID: 26547719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profile of adverse drug reactions in drug resistant tuberculosis from Punjab.
    Bhushan B; Chander R; Kajal NC; Ranga V; Gupta A; Bharti H
    Indian J Tuberc; 2014 Oct; 61(4):318-24. PubMed ID: 25675695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal.
    P V K; Palaian S; Ojha P; P R S
    Pak J Pharm Sci; 2008 Jan; 21(1):51-6. PubMed ID: 18166520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis.
    Wu S; Zhang Y; Sun F; Chen M; Zhou L; Wang N; Zhan S
    Am J Ther; 2016; 23(2):e521-30. PubMed ID: 24284652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors and biomarkers for post-tuberculosis lung damage in a Chinese cohort of male smokers and non-smokers: protocol for a prospective observational study.
    Gai X; Cao W; Rao Y; Zeng L; Xu W; Wu H; Li G; Sun Y
    BMJ Open; 2023 Oct; 13(10):e065990. PubMed ID: 37813532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploratory, cross-sectional social network study to assess the influence of social networks on the care-seeking behaviour, treatment adherence and outcomes of patients with tuberculosis in Chennai, India: a study protocol.
    Nagarajan K; Das B
    BMJ Open; 2019 May; 9(5):e025699. PubMed ID: 31110090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cohort for Tuberculosis Research by the Indo-US Medical Partnership (CTRIUMPH): protocol for a multicentric prospective observational study.
    Gupte A; Padmapriyadarsini C; Mave V; Kadam D; Suryavanshi N; Shivakumar SV; Kohli R; Gupte N; Thiruvengadam K; Kagal A; Meshram S; Bharadwaj R; Khadse S; Ramachandran G; Hanna LE; Pradhan N; Gomathy NS; DeLuca A; Gupta A; Swaminathan S;
    BMJ Open; 2016 Feb; 6(2):e010542. PubMed ID: 26916698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [THE FREQUENCIES AND MANAGEMENT OF ADVERSE REACTIONS IN MULTI-DRUG RESISTANT TUBERCULOSIS TREATMENT].
    Sasaki Y; Yoshiyama T; Okumura M; Morimoto K; Miyamoto M; Irina ; Yoshimori K; Kurashima A; Ogata H; Gotoh H
    Kekkaku; 2017 Jan; 92(1):11-19. PubMed ID: 30646468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-induced lymphocyte stimulation test in the prediction of drug-induced hypersensitivity to antituberculosis drugs.
    Sun Q; Sha W; Gui XW; Xiao YJ; Zeng WH; Sun WW; Xiao HP; Ye WY
    Diagn Microbiol Infect Dis; 2015 Jun; 82(2):172-6. PubMed ID: 25863530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity.
    Warmelink I; ten Hacken NH; van der Werf TS; van Altena R
    Br J Nutr; 2011 Feb; 105(3):400-8. PubMed ID: 20875187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.